Background. The aim of the study was to evaluate the safety and feasibility of intra-arterial mitomycin C (MMC) infusion after selective internal radiation therapy (SIRT) using Yttrium-90 (Y-90) resin microspheres in liver metastatic breast cancer (LMBC) patients.
Patients and methods. The prospective pilot study included LMBC patients from 2012-2018.Patients first received infusion of Y-90 resin microspheres, after 6-8 weeks response to treatment was assessed by MRI, F-18-FDG PET/CT and laboratory tests. After exclusion of progressive disease, MMC infusion was administrated 8 weeks later in different dose cohorts; A: 6 mg in 1 cycle, B: 12 mg in 2 cycles, C: 24 mg in 2 cycles and D: maximum of 72 mg in 6 cycles. In cohort D the response was evaluated after every 2 cycles and continued after exclusion of progressive disease. Adverse events (AE) were reported according to CTCAE version 5.0.
Results. Sixteen patients received Y-90 treatment. Four patients were excluded for MMC infusion, because of extra hepatic disease progression (n = 3) and clinical and biochemical instability (n = 1). That resulted in the following number of patient per cohort; A: 2, B: 1, C: 3 and D: 6. In 4 of the 12 patients (all cohort D) the maximum dose of MMC was adjusted due biochemical toxicities (n = 2) and progressive disease (n = 2). One grade 3 AE occurred after Y-90 treatment consisting of a gastrointestinal ulcer whereby prolonged hospitalization was needed.
Conclusions. Sequential treatment of infra-arterial infusion of MMC after Y-90 SIRT was feasible in 75% of the patients when MMC was administrated in different escalating dose cohorts. However, caution is needed to prevent reflux after Y-90 SIRT in LMBC patients.
- liver metastatic breast cancer
- chemo resistant
- infra-arterial therapy
- selective internal radiation therapy
- mitomycin C infusion
- Y-90 RADIOEMBOLIZATION
- HEPATIC METASTASES
- CENTER EXPERIENCE